DiaSorin Launches its First Onco-Hematology Test on Liaison IAM: The BCR-ABL

Saluggia (VC) - DiaSorin (FTSE Mid Cap:DIA) is pleased to announce that it launched the first onco-hematology molecular diagnostic test for the qualitative detection of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) on its LIAISON IAM, available in the market outside the US and UK only.

The new LIAISON IAM test will offer the benefits of a rapid and reliable detection of the BCR-ABL marker in patient’s blood samples and will be of primary importance for:
- diagnosis of suspected Chronic Myeloid Leukemia in patients that will then be treated with a specific targeted drug (Tyrosin kinase Inhibitors)
- diagnosis of Acute Lymphoblastic Leukemia in patients that will initiate in time the right therapy

In fact, the BCR-ABL marker is the genetic cause of 95% of Chronic Myeloid Leukemia (CML) and 30% of cases of Acute Lymphoblastic Leukemia (ALL). The detection of this marker is mandatory to make the correct diagnosis and, therefore, to implement the right treatment that is able to selectively inactivate the cancer cells.

Paul Eros, Global Vice President of Marketing Molecular DiaSorin, commented: “This is the first in a series of assays in which DiaSorin will use our Q-LAMP molecular amplification technology to provide significant improvements in the time taken to test for hematological malignancies, whilst also improving on sensitivity and specificity. These improvements will allow treating physicians to more accurately tailor therapy to patient need”.

Carlo Rosa, CEO of DiaSorin Group, said: “With the launch of our first onco-hematology product we confirm our strategy of entering this new market with our LIAISON IAM technology that, thanks to its rapid and high quality results, can make the difference in the diagnosis of leukemia, help physicians identify the right treatment and, ultimately, save a life”.